Eliot Forster’s pain biotech unveils Phase 2 data in degenerative joint disease

Reynald Castañeda

Deputy Editor

UK biotech Levicept said its first-in-class biologic can help ease pain and stiffness in patients with moderate to severe osteoarthritis, according to mid-stage data released …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eliot Forster’s pain biotech unveils Phase 2 data in degenerative joint disease

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Stem cell startup spun out of George Church’s lab raises $75M

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Upstream Bio files for IPO in sign of life for biotech public offerings

Edgewise’s stock surges as heart drug passes early safety test

Breaking down silos with a new quantitative approach to drug development

Eliot Forster’s pain biotech un­veils Phase 2 da­ta in de­gen­er­a­tive joint dis­ease

Deputy Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Eliot Forster’s pain biotech unveils Phase 2 data in degenerative joint disease